+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 38 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating treatments for patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms MPNs. This phase II trial compares ASTX727, a combination of cedazuridine and decitabine, given alone or combined with iadademstat. The study aims to assess how these treatments affect leukemia response rates and survival outcomes in patients who have not previously received certain DNA methyltransferase inhibitors. Patients are assigned to one of two groups. One group receives ASTX727 orally once daily on days 1 to 5 of each 28-day cycle. The other group receives the same ASTX727 schedule plus iadademstat orally on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Treatment continues until disease progression or unacceptable side effects occur. Throughout the trial, researchers collect blood, buccal swab, and bone marrow samples to study the disease and treatment effects. Participants have regular assessments including blood tests, bone marrow biopsies, and sample collections over the treatment period. After stopping treatment for reasons other than disease progression, they are followed every 3 months if they stop due to progression, follow-up occurs every 6 months. The main outcome measured is the acute leukemia response rate within 4 treatment cycles. Secondary outcomes include event-free survival, overall survival, and the rate of stem cell transplantation over two years.

Age: 18Years +All GendersPhase 2
32 locations
C

Actively Recruiting

Researchers are studying two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 genetic mutations. This trial compares bilateral salpingectomy, which removes only the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The goal is to find out if removing just the fallopian tubes with delayed ovary removal is nearly as effective as removing both from the start. Participants choose between two groups one undergoes bilateral salpingectomy with the option of later ovary removal, and the other undergoes bilateral salpingo-oophorectomy. Both groups have imaging tests like pelvic ultrasounds or pelvic MRIs during screening and provide blood samples throughout the study. Follow-up visits occur at multiple time points, including 10 to 60 days, 6 months, 12 months, 24 months, and then yearly for up to 20 years. During the study, researchers track if ovarian or related cancers develop and assess symptoms related to estrogen loss, quality of life, cancer-related distress, sexual function, menopausal symptoms, medical decision making, and any adverse events. Various questionnaires and imaging tests support these evaluations. Long-term safety and cancer risk reduction are monitored for up to two decades after surgery.

Age: 35Years - 50YearsFEMALEPhase Not Applicable
574 locations
E

Actively Recruiting

Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.

Age: 12Years +All GendersPhase 3
185 locations
E

Actively Recruiting

Researchers are evaluating GB-0895 as an additional therapy for adolescents and adults with severe asthma that remains uncontrolled despite treatment with inhaled corticosteroids and other standard asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the efficacy and safety of GB-0895 in improving health outcomes for this population, with an optional open-label extension phase. Participants will receive subcutaneous injections of either GB-0895 or a placebo every six months over a 52-week treatment period. The study includes a screening and run-in phase lasting up to five weeks before treatment starts. After the treatment phase, participants will enter a follow-up period lasting from week 52 to week 90 or may opt to join an open-label extension lasting until week 142. During the study, participants will be regularly assessed for asthma exacerbations, lung function changes, quality of life, symptom control, and safety measures including lab tests, vital signs, and ECGs. Researchers will monitor the annualized asthma exacerbation rate as the primary outcome and evaluate additional respiratory and quality of life assessments. The total participation time may extend up to nearly three years for those in the optional open-label extension.

Age: 12Years - 80YearsAll GendersPhase 3
134 locations
E

Actively Recruiting

Researchers are evaluating whether a combination of elranatamab, daratumumab, and lenalidomide provides better clinical benefits compared to a combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in people newly diagnosed with multiple myeloma who cannot have a transplant. This phase 3 study includes two parts the first focuses on safety, tolerability, and dose finding for elranatamab combinations, while the second compares treatment effectiveness and progression outcomes between the two combination therapies. Participants receive different drug combinations depending on the study part and assigned group. Part 1 evaluates elranatamab combined with daratumumab and lenalidomide or elranatamab with lenalidomide alone, focusing on dose levels. Part 2 randomly assigns participants to receive either elranatamab with daratumumab and lenalidomide or the comparator regimen of daratumumab, bortezomib, lenalidomide, and dexamethasone. During the study, participants undergo regular assessments to monitor safety, treatment response, and disease progression, including measuring minimal residual disease negative complete response and progression-free survival. Researchers also track overall survival, adverse events, lab results, drug pharmacokinetics, and quality of life over an extended follow-up lasting up to approximately eight years after randomization.

Age: 18Years +All GendersPhase 3
180 locations
P

Actively Recruiting

Researchers are evaluating de-escalated adjuvant treatment approaches in patients with early-stage endometrial cancer that have either POLE mutations or p53 wildtypeno specific molecular profile NSMP. The study compares new tailored treatments against the usual care, which typically involves surgery followed by analysis of tissue to determine the need for additional radiation or chemotherapy. This phase II trial aims to better understand treatment outcomes based on tumor molecular status. Participants may be enrolled in one of two sub-studies EN10.ARAINBO BLUE for POLE-mutated endometrial cancer and EN10.BTAPER for p53 wildtypeNSMP endometrial cancer. Treatments studied include observation alone, observation with adjuvant radiotherapy using external beam radiation or vaginal brachytherapy delivered through specific devices, and other standard radiation methods. These treatments are delivered following surgical removal of the uterus and ovaries, with treatment starting within 10 weeks post-surgery. During the study, participants will be monitored for pelvic, vaginal, para-aortic, and distant recurrences over a three-year period, as well as survival outcomes up to nine years. Researchers will also assess the impact of molecular classification on fear of cancer recurrence using patient-reported questionnaires. Participants will be followed closely at participating centers through scheduled visits and assessments to track treatment effects and safety throughout the study duration.

Age: 18Years +FEMALEPhase 2
123 locations
S

Actively Recruiting

Researchers are investigating the use of photobiomodulation PBM, a non-invasive infrared light therapy, to reduce stress in people with epilepsy. Epilepsy affects over 50 million individuals worldwide and is often treated with medications that can have significant side effects. This study aims to assess whether PBM can improve brain function, reduce oxidative stress, and promote cellular repair, potentially improving the quality of life for people with epilepsy by lowering their perceived stress levels. Participants will receive PBM using the Vielight Pro 2 device, which delivers pulsed 810nm near-infrared light through a helmet placed on the head and a light emitter clipped to the nostril. The study involves 45 sessions, each lasting 20 minutes, conducted three times a week over 15 to 20 weeks. Some participants will receive active PBM, while others will receive sham fake sessions, with all other procedures identical between groups. The study includes intake, baseline, mid-treatment, post-treatment, and six-month follow-up assessments. Throughout the study, participants will undergo extensive metabolic and behavioral testing, including EEG recordings and various blood, urine, and hair analyses. They will also wear an 5ura ring to monitor sleep and activity continuously. Researchers will measure stress levels using validated psychological inventories and correlate these with objective brain and metabolic data. The total participation lasts about 3 to 4 months, with ongoing monitoring to assess the effects of PBM on stress and brain function in epilepsy.

Age: 18Years +All GendersPhase Not Applicable
4 locations
O

Actively Recruiting

Researchers are evaluating PF-07994525 in participants with relapsed or refractory multiple myeloma RR MM to study its safety, tolerability, how the body processes the drug pharmacokinetics, its effects on the body pharmacodynamics, and its potential antitumor activity. This open-label Phase 1 trial includes a dose escalation phase to find a safe dose and a dose expansion phase to further assess the treatment in more participants with advanced cancers. Participants will receive PF-07994525 orally in two parts Part 1 involves gradually increasing doses to evaluate safety and preliminary antitumor effects, while Part 2 expands the use of the recommended dose from Part 1 to additional participants to continue safety and activity assessments. The study also involves oral administration of Midazolam as part of the treatment evaluation. During the study, participants will be closely monitored for adverse events, laboratory changes, and dose adjustments for up to about two years after treatment. Researchers will assess tumor response using established criteria and collect data on drug concentration and effects over time. Visits will include safety assessments, blood tests, and evaluation of treatment impact, with participation lasting until disease progression, death, or start of new therapy.

Age: 18Years +All GendersPhase 1
26 locations
P

Actively Recruiting

Researchers are evaluating the addition of a stem cell transplant with melphalan after chemotherapy with daratumumab, cyclophosphamide, bortezomib, and dexamethasone Dara-VCD compared to Dara-VCD chemotherapy alone for patients newly diagnosed with amyloid light chain AL amyloidosis. This phase III trial aims to assess outcomes such as major organ deterioration progression-free survival, overall survival, organ response rates, and quality of life. The study also investigates minimal residual disease negativity and treatment-related side effects. Participants initially receive induction therapy with Dara-VCD drugs over a series of 28-day cycles, including daratumumab and hyaluronidase-fihj subcutaneously, bortezomib subcutaneously, cyclophosphamide orally or intravenously, and dexamethasone orally or intravenously. After induction, those with a partial response or better are randomized to one of two consolidation arms either continued Dara-VCD chemotherapy or high-dose melphalan chemotherapy followed by autologous stem cell transplant. Following consolidation, patients receive maintenance daratumumab and hyaluronidase-fihj therapy every 28 days for up to 18 cycles, unless the disease progresses or unacceptable toxicity occurs. Throughout the study, participants undergo multiple assessments including CT, MRI, or PET-CT scans, fat pad biopsies, echocardiography, bone marrow aspiration and biopsies, and blood and urine sample collections at regular intervals. Patient-reported outcomes related to physical function, fatigue, and symptoms are collected using standardized questionnaires. After completing study treatment, patients are followed up every 3 to 6 months for up to 4 years to monitor progression and overall health.

Age: 18Years +All GendersPhase 3
117 locations
C

Actively Recruiting

Researchers are evaluating retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy PRRT compared to usual treatments such as everolimus, sunitinib, or cabozantinib in patients with metastatic, unresectable gastroenteropancreatic neuroendocrine tumors GEPNET who have previously received 177Lu-DOTATATE. This phase II trial aims to assess which treatment better delays tumor progression and improves survival and quality of life in this patient group. PRRT uses a targeted radioactive peptide to kill tumor cells while limiting damage to normal cells. Participants are randomly assigned to one of two study groups. One group receives 177Lu-DOTATATE intravenously every 8 weeks for two cycles if their disease does not worsen or they do not experience severe side effects. The other group takes oral medicationseverolimus daily, or sunitinib for pancreatic NET patients, or cabozantinib for U.S. patientsuntil disease progression or unacceptable toxicity. Imaging scans and blood samples are collected during the study to monitor disease status and treatment effects. Patients whose cancer worsens while on oral medications may cross over to receive 177Lu-DOTATATE. Throughout the trial, participants attend regular visits for CT or MRI scans and blood sample collections. After completing study treatment, they are followed every 12 weeks until the disease progresses and every 6 months thereafter until death. Researchers measure progression-free survival as the main outcome, along with overall survival, response rate, safety, patient quality of life, and other disease progression markers. These assessments will provide comprehensive data on the effects and safety of retreating with 177Lu-DOTATATE compared to other treatments.

Age: 18Years +All GendersPhase 2
43 locations

1-10 of 38

1